Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Michael Patrick Lux

Citation

Annals of Oncology (2019) 30 (suppl_5): v99-v103. 10.1093/annonc/mdz241

Authors

M.P. Lux1, K. Lewis2, A. Rider2, A. Niyazov3

Author affiliations

  • 1 Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, 33098 - Paderborn/DE
  • 2 Adelphi Real World, Adelphi Group Ltd, Cheshire/GB
  • 3 Us Oncology, Pfizer Inc., New York/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4734

Background

Mutations in breast cancer susceptibility gene 1 or 2 (BRCA1/2) are risk factors for developing cancer, especially for breast cancer (BC) and ovarian cancer (OC). Recently, European BC guidelines have expanded the eligibility criteria for BRCA1/2 testing. This study assessed BRCA1/2 testing rates in HER2- adult women with ABC in Germany, France, Italy, Spain and UK (EU5).

Methods

Patient (pt) demographics/clinical characteristics were collected from oncologists in EU5 via Adelphi Advanced Breast Cancer Disease Specific Program. Data collected from 2 years (2015 and 2017) were merged across common variables. Differences in pt demographics/characteristics among BRCA1/2 tested/untested pts were analyzed via t-tests and z-tests. BRCA1/2 testing was analyzed via z-tests. Analyses of BRCA1/2 testing rates were stratified by hormone receptor status [hormone receptor positive (HR+)/HER2- or triple negative breast cancer (TNBC)] and HR status by family history (FHx) of BC or OC.

Results

4,876 records were provided by 742 oncologists. The mean age was 63.6 yrs; 75% HR+/HER2-, 23% TNBC, 2% unknown HR status. Compared to BRCA1/2 untested pts, BRCA1/2 tested pts were younger [57.7 vs 65.2 yrs (p<.001)]and had TNBC [35% vs 20% (p<.001)]. Across all EU5 countries, the mean BRCA1/2 testing rate was 21%; France 20%, Germany 30%, Italy 24%, Spain 20%, UK 14%. Lower BRCA1/2 testing was seen among HR+/HER2- vs TNBC pts [18% vs 33% (p<.001)]. Among HR+/HER2- and TNBC pts, higher BRCA1/2 testing rates were observed among women with a known FHx of BC or OC. (Table). Table. BRCA1/2 Testing by HR Status and known FHx of BC or OC.Table: 292P

HR+/HER2- with FHx (n = 321)HR+/HER2- without FHx (n = 2,953)TNBC with FHx (n = 178)TNBC without FHx (n = 789)
Pts tested, N (%)116 (36)476 (16)99 (56)234 (30)
P value<.001<.001

Conclusions

In this analysis of adult women with ABC, both HR+/HER2- and TNBC pts with a known FHx of BC or OC (vs no known FHx) were more likely to receive BRCA1/2 testing but testing rates are still low especially among HR+/HER2- pts. With the broadening of BRCA1/2 testing eligibility criteria in BC guidelines, opportunities exist to increase BRCA1/2 testing in EU5.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Pfizer Inc.

Funding

Pfizer Inc.

Disclosure

M.P. Lux: Honoraria (self), Advisory / Consultancy: Pfizer Inc.; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: medac; Honoraria (self), Advisory / Consultancy: Grünethal; Honoraria (self), Advisory / Consultancy: Tesaro; Honoraria (self), Advisory / Consultancy: Eisai. A. Niyazov: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.